{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:09:22Z","timestamp":1745035762633,"version":"3.40.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,18]]},"DOI":"10.7759\/cureus.82536","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T20:55:21Z","timestamp":1745009721000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis"],"prefix":"10.7759","author":[{"given":"Syeda Shahmoona","family":"Tirmizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnoor Khalil","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayyaba","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atif A","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu LY","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017, 76:22-8.","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.04.006","article-title":"Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature","volume":"4","author":"Chiang A","year":"2018","unstructured":"Chiang A, Ortenzio F, Juhasz ML, Yu V, Mesinkovska NA. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature. JAAD Case Rep. 2018, 4:733-6. 10.1016\/j.jdcr.2018.04.006","journal-title":"JAAD Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin M","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, et al.. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016, 1:e89776. 10.1172\/jci.insight.89776","journal-title":"JCI Insight"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar A","year":"2012","unstructured":"Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012, 366:1515-25. 10.1056\/NEJMra1103442","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt CH","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017, 3:17011. 10.1038\/nrdp.2017.11","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009","volume":"134","author":"Mirzoyev SA","year":"2014","unstructured":"Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014, 134:1141-2. 10.1038\/jid.2013.464","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8620-9","article-title":"Alopecia areata: a comprehensive review of pathogenesis and management","volume":"54","author":"Tr\u00fceb RM","year":"2018","unstructured":"Tr\u00fceb RM, Dias MF. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2018, 54:68-87. 10.1007\/s12016-017-8620-9","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14940","article-title":"Chronological association between alopecia areata and autoimmune thyroid diseases: a systematic review and meta-analysis","volume":"46","author":"Kinoshita-Ise M","year":"2019","unstructured":"Kinoshita-Ise M, Martinez-Cabriales SA, Alhusayen R. Chronological association between alopecia areata and autoimmune thyroid diseases: a systematic review and meta-analysis. J Dermatol. 2019, 46:702-9. 10.1111\/1346-8138.14940","journal-title":"J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini M","year":"2020","unstructured":"Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020, 29:703-25. 10.1111\/exd.14155","journal-title":"Exp Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.035","article-title":"Frontiers in alopecia areata pathobiology research","volume":"144","author":"Gilhar A","year":"2019","unstructured":"Gilhar A, Laufer-Britva R, Keren A, Paus R. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019, 144:1478-89. 10.1016\/j.jaci.2019.08.035","journal-title":"J Allergy Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: A multifactorial autoimmune condition","volume":"98","author":"Simakou T","year":"2019","unstructured":"Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. J Autoimmun. 2019, 98:74-85. 10.1016\/j.jaut.2018.12.001","journal-title":"J Autoimmun"},{"key":"ref12","article-title":"JAK inhibitors for the treatment of alopecia areata (Article in Hebrew)","volume":"159","author":"Ramot Y","year":"2020","unstructured":"Ramot Y, Zlotogorski A. JAK inhibitors for the treatment of alopecia areata (Article in Hebrew). Harefuah. 2020, 159:38-42.","journal-title":"Harefuah"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.027","article-title":"Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series","volume":"77","author":"Park HS","year":"2017","unstructured":"Park HS, Kim MW, Lee JS, Yoon HS, Huh CH, Kwon O, Cho S. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol. 2017, 77:978-80. 10.1016\/j.jaad.2017.06.027","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow BG","year":"2017","unstructured":"Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017, 76:29-32. 10.1016\/j.jaad.2016.09.006","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.041","article-title":"Tofacitinib therapy for children with severe alopecia areata","volume":"80","author":"Dai YX","year":"2019","unstructured":"Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol. 2019, 80:1164-6. 10.1016\/j.jaad.2018.12.041","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13598","article-title":"Efficacy of tofacitinib in treatment of alopecia universalis in two patients","volume":"30","author":"Gupta AK","year":"2016","unstructured":"Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016, 30:1373-8. 10.1111\/jdv.13598","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan J","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, et al.. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016, 1:e89790. 10.1172\/jci.insight.89790","journal-title":"JCI Insight"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70195-7","article-title":"Alopecia areata investigational assessment guidelines","volume":"40","author":"Olsen E","year":"1999","unstructured":"Olsen E, Hordinsky M, McDonald-Hull S, et al.. Alopecia areata investigational assessment guidelines. J Am Acad Dermatol. 1999, 40:242-6. 10.1016\/s0190-9622(99)70195-7","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5021\/ad.24.058","article-title":"Korean consensus criteria for the severity classification of alopecia areata","volume":"36","author":"Jang YH","year":"2024","unstructured":"Jang YH, Lee SS, Park DY, et al.. Korean consensus criteria for the severity classification of alopecia areata. Ann Dermatol. 2024, 36:236-46. 10.5021\/ad.24.058","journal-title":"Ann Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.13418","article-title":"Effectiveness of tofacitinib in pre-adolescent alopecia areata: a retrospective case series and literature review","volume":"103","author":"Huang J","year":"2023","unstructured":"Huang J, Li T, Tan Z, Tang Y, Li J, Liu F, Shi W. Effectiveness of tofacitinib in pre-adolescent alopecia areata: a retrospective case series and literature review. Acta Derm Venereol. 2023, 103:adv13418. 10.2340\/actadv.v103.13418","journal-title":"Acta Derm Venereol"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.53350\/pjmhs20221612801","article-title":"A study on the role of tofacitinib among patients treated with alopecia areata","volume":"16","author":"Kiyani AJ","year":"2022","unstructured":"Kiyani AJ, Shaikh HA, Mirza U, Awan S, Saqib A. A study on the role of tofacitinib among patients treated with alopecia areata. Pak J Med Health Sci. 2022, 16:801-3.","journal-title":"Pak J Med Health Sci"},{"key":"ref23","article-title":"Long-term treatment with tofacitinib in severe alopecia areata: an update","volume":"12","author":"Hogan S","year":"2019","unstructured":"Hogan S, Wang S, Ibrahim O, Piliang M, Bergfeld W. Long-term treatment with tofacitinib in severe alopecia areata: an update. J Clin Aesthet Dermatol. 2019, 12:12-4.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.2019.19.01.015","article-title":"The role of tofacitinib in the management of alopecia totalis","volume":"19","author":"Hernandez-Montoya C","year":"2019","unstructured":"Hernandez-Montoya C, Ruiz-Villaverde R. The role of tofacitinib in the management of alopecia totalis. Sultan Qaboos Univ Med J. 2019, 19:e77-8. 10.18295\/squmj.2019.19.01.015","journal-title":"Sultan Qaboos Univ Med J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_26_19","article-title":"Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata","volume":"38","author":"Dai YX","year":"2020","unstructured":"Dai YX, Yeh CP, Chen CC. Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata. Dermatol Sin. 2020, 38:3-8. 10.4103\/ds.ds_26_19","journal-title":"Dermatol Sin"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3329\/jafmc.v18i1.61257","article-title":"The usefulness and wellbeing of tofacitinib in the treatment of alopecia areata","volume":"18","author":"Khondker L","year":"2022","unstructured":"Khondker L, Sultana A, Khan MS. The usefulness and wellbeing of tofacitinib in the treatment of alopecia areata. J. Armed Forces Med. Coll. 2022, 18:43-7. 10.3329\/jafmc.v18i1.61257","journal-title":"J. Armed Forces Med. Coll"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","volume":"34","author":"Guo L","year":"2020","unstructured":"Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020, 34:192-201. 10.1111\/jdv.15937","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14422","article-title":"Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study","volume":"38","author":"Jerjen R","year":"2021","unstructured":"Jerjen R, Meah N, Trindade de Carvalho L, Wall D, Eisman S, Sinclair R. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study. Pediatr Dermatol. 2021, 38:103-8. 10.1111\/pde.14422","journal-title":"Pediatr Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2023.13.02072202313022023","article-title":"Analyzing the role of tofacitinib in treatment of alopecia areata: a retrospective analysis from a tertiary care center of North India","volume":"13","author":"Singla S","year":"2023","unstructured":"Singla S, Narang R, Shanker V, Gupta S, Saraswat N, Singh R. Analyzing the role of tofacitinib in treatment of alopecia areata: a retrospective analysis from a tertiary care center of North India. Natl J Physiol Pharm Pharmacol. 2023, 13:1854-7. 10.5455\/njppp.2023.13.02072202313022023","journal-title":"Natl J Physiol Pharm Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336838-efficacy-of-oral-tofacitinib-in-alopecia-areata-alopecia-totalis-and-alopecia-universalis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T20:55:22Z","timestamp":1745009722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336838-efficacy-of-oral-tofacitinib-in-alopecia-areata-alopecia-totalis-and-alopecia-universalis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.82536","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}